Abstract: To provide a two-paste type sealer composition for root canal filling consisting of a first paste containing a polymer (a) of an acid group-containing polymerizable monomer in which a portion or the entirety of the acidic group in a molecule forms a salt with an alkaline metal, a non-acid reactive powder (b) and water (c), wherein the pH of the first paste is in the range from 3.5 to 5.5, and a second paste containing an acid reactive inorganic powder (d), water (c) and a thickener (e), wherein, a cured product of a kneaded material of the first paste and the second paste comprises 3 to 20 part by weight of the polymer (a), 15 to 60 part by weight of the water (c), and 30 to 70 part by weight of the acid reactive inorganic powder (d).

Abstract: Disclosed herein is a dental impression material that includes a two part addition curing silicone composition. The disclosed impression material contains a surfactant system composed of a fluorosurfactant and a fatty alcohol ethoxylate. The impression material disclosed herein exhibits improved storage stability than known systems using fluorosurfactants and silicone ether compounds.

Abstract: A skin smoothing film made from a skin smoothing composition that comprises sodium silicate, polyvalent silicate and water. Moreover, the film may be made from a composition that has a contraction value of from about 30% to about 160%. The film thickness is from about 5 microns to about 50 microns, preferably from about 10 microns to about 40 microns, when applied. The standard deviation of the film over the area covered is less than about 30, preferably less than about 25.

Abstract: A bio cellulose membrane with an outstanding water retention capacity and a method for producing the same are provided. The bio cellulose membrane comprises a first surface, a second surface, and a loose layer, wherein the average pore size of the first surface and the average pore size of the second surface are smaller than that of the loose layer.

Abstract: A varnish composition is provided comprising a hydrophilic oral care agent, such as a peroxide material, dispersed in a solution of a film-forming hydrophobic polymer in a non-polar solvent. The solvent is selected so as to be a good solvent for the polymer and to be susceptible to evaporation. The composition can be applied as a single layer varnish, preferably a whitening varnish. E.g., the dispersed hydrophilic peroxide material is an aqueous peroxide solution, such as a hydrogen peroxide solution, whereby the dispersion is an emulsion.

Abstract: The skin serves as a barrier that protects the body from the external environment and prevents water loss. This barrier function also prevents most hydrophilic or hydrophobic and large molecular weight ingredients (>500 kDa) from penetrating intact skin. Until recently, methods to increase stratum corneum permeability were generally not effective enough to make the stratum corneum so permeable that the barrier posed by the viable epidermis mattered. However, that has now changed with the development of the present embodiment's physical methods and highly optimized chemical formulations, such that we revisited the permeability of the full epidermis with the example embodiment's constructs and not focus only on the stratum corneum. This example embodiment therefore tests the hypothesis that the viable epidermis offers a significant permeability barrier to both small molecules and macromolecules that becomes the rate limiting step.

Abstract: This invention concerns a calcium polyphosphate material consisting of amorphous nanoparticles with a diameter of approximately between about 45 nm to about 0.25 ?m that displays a considerable hardness (elastic modulus) of about 1.3 GPa. The inventive noncrystalline and biodegradable material that is produced under mild conditions, at room temperature, is morphogenetically active and preferably induces bone formation and the expression of the marker gene for osteoblast activity, alkaline phosphatase. In a preferred aspect, the invention concerns a method for producing amorphous retinol/calcium-polyphosphate nanospheres (retinol/aCa-polyP-NS) that show several unexpected properties and can be used in the treatment or prophylaxis of a variety of dermatological conditions, including photoaging.

Abstract: Substrates having formulations disposed thereon, wherein the formulations have improved transfer rates from the substrate to skin, are disclosed herein. More particularly, the formulations can be applied to nonwoven, particularly elastomeric substrates, as well as tissue paper, and can be easily and efficiently transferred from the substrate to the skin of a user upon intimate contact thereto. Laminated articles using one or more of the substrates having the formulations disposed thereon are further disclosed.

Abstract: A composition including water, about 0.1% to about 0.4% of a 4-substituted resorcinol, an ester having at least about 25 carbon atoms, and a polymeric emulsifier is provided. The composition comprises less than about 5% by weight of oils and is substantially free of monomeric emulsifier. Methods of treating the skin are also provided.

Abstract: The present invention relates to novel compounds of formula (I) to compositions comprising same, and also to the use thereof for preventing and/or cosmetically treating the signs of aging of the skin.

Abstract: The present disclosure concerns a multi-component packing unit (kit of parts) for reshaping and coloring keratinous fibers, more particularly human hair, comprising at least two separately packaged preparations (A) and (B), the first preparation (A) comprising, in a cosmetic vehicle (A1), one or more resorcinol derivatives from the group consisting of resorcinol, 2-methylresorcinol and 4-chlororesorcinol, and (A2) one or more oxidation dye precursors from the group consisting of p-phenylenediamines, p-aminophenols, 2,4,5,6-tetraaminopyrimidines and 4,5-diaminopyrazoles, and the second preparation (B) comprising, in a cosmetic vehicle (B1), hydrogen peroxide, wherein the molar ratio of all resorcinol derivatives (A1) in the preparation (A) to all developer-type oxidation dyes (A2) in the preparation (A), i.e. the molar ratio (A1)/(A2), is at least about 1.2.

Abstract: The present invention provides novel N-aralkylcarbonyldiamine compounds having a structure as set forth in Structure I. The structures are not quaternized. When these novel unquaternized compounds are used in personal care compositions, particularly personal care skin compositions, they are more stable and provide unexpected cosmetic advantages (e.g., against wrinkles, aging skin, etc.) when delivered from the personal care skin compositions.

Abstract: Provided are: a method for producing a mycrosporine-like amino acid (MAA) that includes a step in which microbes are cultivated that produce MAA on the outside of bacterial cells, a step in which the bacterial cells and extracellular culture fluid are separated, and a step in which the MAA is recovered from the extracellular culture fluid; an MAA indicated by formula (1), an MAA produced using this method, or an ultraviolet-absorbing composition including the MAA indicated by formula (1); and a composition including the MAA produced using this method or the MAA indicated by formula (1), for preventing at least one symptom or disease selected from a group comprising acute skin reactions, aging of the skin, and skin cancer.

Abstract: The disclosure relates to an oral care composition an effective amount of at least one C?1-4#191 (optionally hydroxylated) alkyl glycoside, e.g., ?-methyl-D-galactoside, wherein the glycoside promotes the growth of beneficial endogenous bacteria and negatively affects the growth of endogenous pathogenic strains of bacteria. The disclosure also relates to methods of use, methods of screening, and methods of manufacture of said oral care compositions.

Abstract: The present invention relates to an oral composition having an enhanced solubility of an alkyl galactoside while holding an inhibiting effect on coaggregation of the alkyl galactoside well. The present invention provides an oral composition comprising the following components: (A) 0.001 mass % or more and 1 mass % or less of a compound represented by the following formula (I): wherein R is an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G is a galactose residue, E is a hydrogen atom or a methyl group, m is an integer of 0 to 200, and n is an integer of 1 to 30; (B) 0.001 mass % or more and 0.1 mass % or less of a cationic bactericide; and (C) 35 mass % or more of water.

Abstract: The present invention relates to the composition and method of use for the topical application of the potent androgen hormone dihydrotestosterone (DHT), used alone or in fixed combination with other hair growth medications; including other androgens, bimatoprost, other prostamides, prostaglandins, minoxidil or apocrine hair growth factors to promote and enhance hair growth of terminal mustache hair, beard hair, also chest hair, and other male androgen sensitive or dependent hair growth in humans or animals.

Abstract: The present invention relates to the composition and method of use for the topical application of the potent androgen hormone dihydrotestosterone (DHT), used alone or in fixed combination with other hair growth medications; including other androgens, bimatoprost, other prostamides, prostaglandins, minoxidil or apocrine hair growth factors to promote and enhance hair growth of terminal mustache hair, beard hair, also chest hair, and other male androgen sensitive or dependent hair growth in humans or animals.

Abstract: The present invention relates to a vesicle containing a saccharide isomerate, a hydrolyzed lupine protein, and an intercorneocyte lipid mimetics as an active ingredient, and a composition for skin external application including the vesicle, and more particularly, to a vesicle including: an aqueous phase part including a saccharide isomerate and a hydrolyzed lupine protein; and an oil phase part including an intercorneocyte lipid mimetics, lysolecithin, and glycerin. The vesicle includes the intercorneocyte lipid mimetics together with the saccharide isomerate and the hydrolyzed lupine protein as contents, so that the vesicle is excellent in a skin barrier recovery function and a skin moisturizing effect upon skin application. In addition, the vesicle is excellent in phase stability, so that the vesicle is suitable to be commercialized as various compositions for skin external application.

Abstract: The present invention relates to a crosslinked hyaluronic acid gel which derives from the crosslinking of hyaluronic acid or of a salt thereof in the presence of at least an effective amount of at least one endogenous polyamine as a crosslinking agent, said crosslinking being carried out under conditions favorable to the coupling of said hyaluronic acid and of said endogenous polyamine(s).

Abstract: A dentifrice composition containing a polyethylene glycol having an average molecular weight of from about 3,000 to about 8,000, glycerin, precipitated silica, and a fluoride source. The polyethylene glycol forms a crystalline structure in the composition and the composition has a water activity from about 0.25 to about 0.46 measured at about 22° C.

Abstract: The invention relates to nail compositions comprising at least one silicone-organic polymer hybrid compound and at least one alkyd resin.

Abstract: Provided is a cosmetic use, as deodorant active agent, of an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, and in particular an essential oil of Satureja montana L. ssp. variegata or Satureja Montana var. citrodoria oil. Also provided is a cosmetic method for treating human body odors, in particular the armpits or feet, which comprises applying, to human keratin materials, at least one Satureja montana essential oil comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, and in particular an essential oil of Satureja montana L. ssp. variegata or Satureja Montana var. citrodoria oil or a composition containing same in a cosmetically acceptable medium.

Abstract: A method useful for inhibiting moisture loss from skin comprises the step of administering a composition to a subject's skin. The composition comprises a first humectant and a second humectant different from the first humectant. The humectants are useful for increasing moisture content of the subject's skin, specifically the subject's epidermis. The first humectant may comprise a conventional humectant, e.g. glycerol. The second humectant generally comprises certain types of honey. The honey is capable of inhibiting moisture loss from the subject's epidermis and/or moisture loss from the first humectant when the subject is exposed to dry air conditions, e.g. wintertime air having a relative humidity of about 50% or less. Specifically, the second humectant is useful for mitigating adverse effects of the first humectant under certain conditions.

Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.

Abstract: An antimicrobial polymer for use in an ophthalmic implant, includes at least one antimicrobial monomer; and at least one other monomer selected from an acrylic, silicone, vinyl and collagen monomer.

Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Abstract: Non-adhesive particles as large as 110 nm can diffuse rapidly in the brain ECS, if coated with hydrophilic coatings such as PEG coatings and preferably having neutral surface charge. The ability to achieve brain penetration with larger particles will significantly improve drug and gene delivery within the CNS since larger particles offer higher drug payload, improved drug loading efficiency, and significantly longer drug release durations.

Abstract: Provided is a drug delivery system for control of initial burst of a drug. More particularly, there are provided a drug delivery formulation including: a granule containing a biodegradable polymer and a drug; and a temperature-sensitive hydrogel, and a method for preparing the same. The presently disclosed drug delivery formulation can be prepared via a relatively simple process and allows a drug to be released slowly at a constant rate without initial burst and thus maintains a constant blood level of the drug for a long period of time. Consequently, it is capable of preventing the initial burst of the existing injection-type drug delivery formulations and slow-release granules and providing a desired release profile, including sustained release with time.

Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.

Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.

Abstract: The instant invention provides for novel cationic lipids of Formula A that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: Adhesive formulations are provides for manufacturing matrix-type lidocaine patches having improved performance, manufacturability and stability.

Abstract: A patch including: a support; and an adhesive layer disposed on at least one surface of the support, in which the adhesive layer includes: at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof; a higher aliphatic alcohol; and a non-cross-linking polyvinylpyrrolidone that does not contain vinyl acetate as a constituent monomer thereof.

Abstract: The invention relates to a transdermal therapeutic system, comprising a back layer that is impermeable to an active ingredient, a polymer matrix containing the active ingredient, and a protective layer that can be pulled off, wherein 5-aminolevulinic acid hydrochloride is used as the active ingredient and the basic polymer of the polymer matrix is an adhesive polyacrylate. Said transdermal therapeutic system is suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of IL-17A, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model. Therefore, these compounds can be used for the treatment of autoimmune diseases mediated by IL-17.

Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Abstract: A gelling formulation containing ketamine or a pharmaceutically acceptable salt thereof in water, a poloxamer and one or more pharmaceutically acceptable mucoadhesive agents is provided. Also provided is a method of using the formulation for pain treatment.

Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: D-serine is used to treat a neurological disorder, such as epilepsy, that cases seizures. A composition comprising D-serine is artificially administered to a patient in an effective amount by selectively contacting a region of the patient's brain with the composition. The region of the brain selectively contacted with the composition has cells expressing GluN3 subunit-containing triheteromeric NMDARs.

Abstract: Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.

Abstract: The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.

Abstract: The present invention relates to a method of synthesizing sulforaphane by reacting a compound of formula (A) with an oxidizing agent in an aqueous solvent and in the presence of a catalyst. The invention further provides a method of synthesizing a stabilized complex of sulforaphane and cyclodextrin by mixing the sulforaphane prepared by the methodology defined herein with cyclodextrin in an aqueous solvent.

Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.

Abstract: The disclosed invention generally relates to treatment and/or prevention of symptoms associated with cannabinoid responsive diseases and disorders in subjects in need thereof, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids. The disclosed invention further relates to pharmaceutical compounds for treating and/or preventing symptoms associated with said diseases and disorders.

Abstract: The present invention provides applications of a small molecular flavonoid compound in preparing a medication for sensitizing/synergizing tumor radiation therapy as well as reducing radioactive damage. The small molecular flavonoid compound can be naringenin, hesperetin, luteolin and apigenin, etc. The medication contains a small molecular flavonoid compound and a plurality of conventional pharmaceutical additives; wherein the small molecular flavonoid compound is an active ingredient.

Abstract: A dosage delivery film composition containing a botanical drug substance formable into a bioerodible dosage delivery film, the dosage delivery film composition including: (i) one or more of: a polymer, a plasticizer, a defoamer, or an antioxidant; (ii) a cannabinoid-cyclodextrin-terpene complex or a cannabinoid-terpene-surfactant micelle, and (iii) optionally, one or more of: a taste mask, a vasodilator, or a lipophilic vehicle to transport the botanical drug substance across the mucous membrane.

Abstract: A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.